Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.

Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.

In the ever-evolving landscape of corporate finance, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Pfizer Inc. and Walgreens Boots Alliance, Inc. have demonstrated distinct strategies in this domain. From 2014 to 2023, Walgreens consistently outpaced Pfizer in SG&A expenses, with a notable 43% higher average annually. This trend highlights Walgreens' expansive operational scale and strategic investments in administrative functions. Interestingly, Pfizer's SG&A expenses saw a dip in 2020, coinciding with global economic shifts, before rebounding by 27% in 2023. Meanwhile, Walgreens' expenses peaked in 2024, reflecting a 59% increase from 2014. These insights underscore the dynamic nature of cost management in the pharmaceutical and retail sectors, offering a window into the strategic priorities of these industry giants.